Nerve microvessel changes in diabetes are prevented by aldose reductase inhibition.
BACKGROUND
Despite the potential importance of endoneurial microvessel abnormalities in diabetic neuropathy, the pathogenesis of these abnormalities is incompletely understood. We wished to evaluate the effect of experimental diabetes on endoneurial microvessels and determine if an aldose reductase inhibitor alters any of the changes induced by diabetes.


METHODS
We compared streptozocin diabetic rats with and without aldose reductase inhibitor treatment to non-diabetic rats after 10 months of diabetes. Transverse microvessels from the mid-sciatic level were studied by electron microscopic morphometric evaluation.


RESULTS
Microvessel endothelial, pericyte, basement membrane and total mural area were greater in untreated diabetic animals than non-diabetic animals. Aldose reductase inhibitor treated diabetic animals had greater endothelial area and possibly pericyte area but not basement membrane or total mural area.


CONCLUSIONS
This study demonstrates that endoneurial microvessel abnormalities can be detected in experimental diabetic neuropathy. Microvessel basement membrane thickening will be prevented by an aldose reductase inhibitor. One mechanism by which abnormal polyol pathway activity may contribute to diabetic neuropathy could be through damage to microvessels.
Benstead
T J
TJ
Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Sangalang
V E
VE
D000449:Aldehyde Reductase / Q000187:drug effects*; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D008297:Male; D008854:Microscopy, Electron; D009412:Nerve Fibers / Q000378:metabolism*; D010525:Peripheral Nerves / Q000378:metabolism* / Q000648:ultrastructure; D051381:Rats; D017207:Rats, Sprague-Dawley
D004791:Enzyme Inhibitors; D000449:Aldehyde Reductase